Open Access

Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma

Experimental Hematology & Oncology20176:29

https://doi.org/10.1186/s40164-017-0089-y

Received: 7 September 2017

Accepted: 27 October 2017

Published: 6 November 2017

Abstract

Background

The treatment algorithm for metastatic non-small cell lung cancers (NSCLCs) has been evolving rapidly due to the development of new therapeutic agents. Although guidelines are provided by National Comprehensive Cancer Network (NCCN) for treatment options according to biomarker testing results, sequentially applying the three main modalities (chemotherapy, targeted therapy and immunotherapy) remains an ad hoc practice in clinic. In light of recent FDA approval of dabrafenib and trametinib combination for metastatic NSCLCs with BRAF V600E mutation, one question arises due to insufficient clinical data is if the targeted therapy should be used before immunotherapy in patients with both BRAF V600E and PD-L1 expression.

Case presentation

We present a case of 74-year-old female, former smoker with metastatic lung adenocarcinoma. The BRAF V600E mutation among other abnormalities was identified by comprehensive genomic profiling. The patient had an excellent 2-year response to the combination of pemetrexed and sorafenib. The patient was then treated with dabrafenib due to the presence of the BRAF V600E mutation and intolerance to cytotoxic chemotherapy. Not only the patient had an 18-month durable response to dabrafenib, she experienced outstanding quality of life with no serious adverse effects. At the time of symptomatic progression, the patient was then treated with two cycles of pembrolizumab based on her positive PD-L1 staining (90%). She had early response and came off pembrolizumab due to side effects. Seven months after initiation of pembrolizumab, the patient is off all the therapy and is currently asymptomatic. The patient is surviving with metastatic disease for over 7 years as of to date.

Conclusions

By appropriately sequencing the three main modalities of systemic therapies, we are able to achieve long-term disease control with minimal side effects even in a geriatric patient with multiple comorbidities. We argue that it is reasonable to first use a BRAF inhibitor before considering immunotherapy for NSCLCs positive for both BRAF V600E and PD-L1.

Keywords

Non-small cell lung cancerBRAF V600EPD-L1Targeted therapyImmunotherapySequential treatment

Background

The treatment paradigm for metastatic non-small cell lung cancers (NSCLCs) has been evolving rapidly due to new therapeutic options [1]. In metastatic, non-small cell, non-squamous lung cancer patients, three groups can be defined based on tumor molecular testing results, each paired with a specific first-line systemic therapy of proven clinical benefit. Patients in the first group are positive for sensitizing EGFR mutations, ALK or ROS1 rearrangement with the matched targeted tyrosine kinase inhibitors (TKIs) as the first-line treatment. In the second group, patients are PD-L1 immunohistochemistry positive (≥ 50%) and EGFR, ALK, ROS1 negative, and single agent pembrolizumab is a FDA-approved first-line therapy. Patients in the third group are EGFR, ALK, ROS1, and PD-L1 negative, paired with systemic chemotherapy plus or minus pembrolizumab as the first-line option. Significant progress has also been made to develop predictive biomarkers for PD-1/PD-L1 immune checkpoint blockade therapy [2, 3].

In addition to EGFR, ALK and ROS1, emerging evidences have demonstrated clinical benefit to therapies against BRAF [47], MET [810], RET [11, 12] or HER2 [13, 14] in NSCLCs harboring activating mutations. Most notably, FDA approved dabrafenib and trametinib combination for metastatic NSCLCs with BRAF V600E mutation on June 22, 2017 (https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564331.htm). In light of this recent regulatory approval, one question arises due to insufficient clinical data is if the targeted therapy should be used before immunotherapy in patients with both BRAF V600E and PD-L1 expression.

Case presentation

A 74-year-old female, former smoker had resected stage III lung adenocarcinoma and was treated with adjuvant concurrent chemoradiation with carboplatin and paclitaxel in 2008 (Fig. 1). The patient’s surgical resection specimen was tested for EGFR amplification by FISH (ARUP Laboratories) and KRAS mutation analysis (GenPath Diagnostics), and the results indicated EGFR was non-amplified and KRAS was wild type at codons 12, 13, and 61. Her medical history includes hypertension, hyperlipidemia, GERD (gastroesophageal reflux disease), SVT (supraventricular tachycardia), chronic kidney disease and osteoporosis. The patient developed metastatic recurrent lung cancer with malignant pleural effusion in 2010. The EGFR mutation analysis by real-time PCR (Clarient Diagnostic Services) was done on the pleural effusion specimen and none of the 29 known mutations, deletions and insertions found in exons 18–21 of the EGFR tyrosine kinase domain was detected. The patient was then treated with pemetrexed and sorafenib on trial (NCCTG N0626 study, http://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.7513) with a durable response for more than 2 years (Fig. 1). The treatment was stopped in 2012 due to intolerance. Afterwards, the patient was on observation for 2 years until she developed symptomatic progression with extensive bony metastasis in 2014 (Figs. 1, 2a). Her left pelvic metastasis biopsy specimen was used for genomic profiling and PD-L1 staining (see below). She was treated with palliative radiation, followed by carboplatin and pemetrexed. Cytotoxic chemotherapy was discontinued after 2 months due to profound toxicities which required hospitalization, despite of dose reductions (Fig. 1).
Fig. 1

Oncology history of the patient

Fig. 2

a PET scan of the patient before initiation of dabrafenib reveals metastatic disease to the left iliac bone, C2 and L3-4 vertebral bodies. The C2 lesion’s SUV max was 7; the lesion at L3 had a SUV max of 7.1; the left acetabulum lesion’s SUV max was 5.1 prior to starting dabrafenib. b After 4 months of dabrafenib therapy, near complete resolution of PET activity in the areas of bone metastases was demonstrated without any new site of disease. Upon the best response to dabrafenib achieved, the metabolic activity resolved at C2 and L3 lesions. The left acetabulum lesion only had a very small focus of residual uptake that the max SUV was not measured

To explore additional therapeutic options, we then performed comprehensive genomic profiling (CGP) using the FoundationOne ® panel (http://foundationone.com/). The CGP identified the BRAF V600E mutation as well as inactivating mutations in tumor suppressors including ATM. In addition, the tumor mutation burden was low—five per megabase and the tumor was microsatellite stable (MSS). The full report of the CGP is provided as Additional file 1. Based on this genetic profile, the patient was started on dabrafenib [7] in April 2015 (Fig. 1). Dabrafenib was used at 150 mg PO BID throughout the treatment course. She had excellent clinical and radiographic responses (Fig. 2b). Her performance status drastically improved. Her only noticeable side effect was hypokalemia that was managed with oral and IV potassium replacement. The patient developed increase of metabolic activity from two disease sites on PET scan suggestive of disease progression without clinical symptoms 7 months after initiation of dabrafenib. Based on the phase II trial [6] reported in 2015 ASCO annual meeting demonstrating activity of dabrafenib and trametinib combination in BRAF mutated lung cancers, our patient was offered the addition of trametinib. However, she did not tolerate the combination and stopped trametinib after 1 week. The patient was asymptomatic from her metastatic lung cancer until the 19th month into the dabrafenib therapy, when she developed productive cough and restaging scan revealed new hypermetabolic upper abdominal lymph node metastases at the gastrohepatic ligament, precaval and peripancreatic retroperitoneum (Fig. 1).

The patient was discontinued from dabrafenib and started on pembrolizumab based on her positive PD-L1 staining (90%) in December 2016 (Fig. 1). The treatment was complicated by immune mediated colitis and pneumonitis which promptly responded to systemic steroids. The dose and duration of steroids used for treating pneumonitis are as follows: prednisone 40 mg daily for 1 weeks, followed by 20 mg daily for 5 days, 10 mg daily for 5 days, 5 mg daily for 5 days, then off. Her colitis was successfully treated in the similar fashion. A repeat CT scan 12 days after initiation of pembrolizumab was done for the work-up of abdominal pain, confirmed colitis, but also demonstrated decreased size of the gastric hepatic ligament node and resolution of the peripancreatic nodule, consistent with early response. She was able to stop steroid and became asymptomatic from her disease and prior treatment effects in March 2017. As of July 2017, the patient has no signs of disease progression after only two doses of pembrolizumab (200 mg IV) 7 weeks apart without additional therapy (Fig. 1). The patient has not had any hospitalization after the initiation of dabrafenib. It is noted that a recent pooled analysis of advanced melanoma (http://ascopubs.org/doi/abs/10.1200/JCO.2017.73.2289) also showed the patients who discontinued PD-1 checkpoint blockade antibodies continue to benefit from the treatment.

Discussion and conclusions

We present a case of BRAF V600E positive and PD-L1 positive metastatic lung adenocarcinoma. The patient exhibited excellent response for more than 18 months to single agent dabrafenib. Although serious adverse events (AEs) were observed in 42% of patients in the single-arm, phase II trial of dabrafenib [7] with skin toxicities as the most frequent grade 3 or worse AEs, the patient in our case only displayed manageable hypokalemia with no skin toxicity.

Prior to dabrafenib, the patient also demonstrated 2-year response to a pemetrexed and sorafenib based regimen. After the treatment was stopped, the patient had another 2 years of stable disease before disease progression. This excellent response could be partially due to the presence of the BRAF V600E mutation. Although previous phase III studies of sorafenib in NSCLC failed to meet primary end points [15], BRAF mutation status was neither used in trial design nor analyzed retrospectively as a biomarker. Our results suggest BRAF activating mutations could be a patient stratification marker in NSCLC trials incorporating sorafenib. Notably, a recent case report demonstrated efficacy of sorafenib in a NSCLC harboring activating BRAF G469V mutation, but no response in synchronous BRAF wild type-hepatocellular carcinoma [16].

As our patient was positive for PD-L1 (90%), pembrolizumab treatment was initiated and the patient demonstrated response with stable disease radiographically. Since the tumor harbors an inactivating mutation in ATM, the response to anti-PD1 therapy is also consistent with previous studies that DNA repair deficiency predicts immunotherapy response [17, 18]. Interestingly, our patient has a low tumor mutation burden (TMB). The presence of the BRAF V600E mutation, high PD-L1 expression, and response to pembrolizumab in our case supports a recent preliminary report (http://www.abstractsonline.com/pp8/#!/4292/presentation/1306) that TMB-low/PD-L1-high NSCLCs are enriched for BRAF mutations suggesting BRAF alterations in this group may trigger immune responses moderated by PD-L1 expression.

Systemic chemotherapy in advanced NSCLC results in a median overall survival (OS) of only 8 to 12 months and a median progression-free survival (PFS) of 5 to 6 months [1921]. First line targeted TKIs significantly improved outcome: 10–14 months of PFS and 20–32 months of OS for EGFR-TKIs [2227], and 15.3 months of PFS and 36.8 months of OS (http://abstracts.asco.org/199/AbstView_199_183873.html) for ALK-TKIs. It is remarkable that our patient is surviving with metastatic lung cancer for over 7 years as of to date. From this case, we argue that it is reasonable to consider a BRAF inhibitor before utilizing immunotherapy in patients with BRAF V600E-positive and PD-L1 positive metastatic NSCLC. Our patient had excellent quality of life and more than 18 months of disease control on a BRAF inhibitor. She has been free of hospitalization and emergency room visit since the initiation of dabrafenib. This demonstrated a successful case of transitioning advanced lung cancer into a chronic disease. The advent of targeted therapy and immunotherapy made it possible to achieve long-term disease control with minimal side effects even in a geriatric patient with multiple comorbidities. Appropriately sequencing the three main modalities of systemic therapies (cytotoxic chemotherapy, targeted therapy and immunotherapy) to achieve long-term disease control and minimize side effect is the ultimate goal in modern age of lung cancer care, and this case report provides practicing oncologists a valuable reference.

We should also point out that in addition to considering each therapeutic modality individually, there are significant efforts to explore combination of immunotherapy plus standard chemotherapy or combination of immunotherapy plus radiotherapy [2830]. For example, in a phase II study of pembrolizumab in combination with carboplatin and pemetrexed in chemotherapy-naïve, advanced non-squamous NSCLCs, the pembrolizumab plus chemotherapy group achieved an objective response rate of 55% in comparison to 29% in the chemotherapy alone group while the incidence of grade 3 or worse treatment-related adverse events was similar between the two groups [29]. Progression-free survival was also significantly longer with pembrolizumab plus chemotherapy compared with chemotherapy alone [29]. In a phase I study, radiation therapy in combination with pembrolizumab is evaluated (NCT02318771), and immune biomarkers for treatment failure in a specific case was reported [28]. Collectively, these studies may represent a future direction to develop more effective treatment options for NSCLCs.

We recognize the limitation of a single case report and several factors one should take into considerations. Although our case suggests sequencing BRAF-TKIs followed by pembrolizumab might be considered for advanced NSCLCs positive for both BRAF V600E and PD-L1, this is only a single case for which the clinical decision was made based on this particular patient’s prior treatment history, response and side effects. Additional clinical studies are needed to provide more clinical evidences. In metastatic NSCLCs driven by other oncogenes with available matched TKIs, the patients often do not benefit from immunotherapy. For example, a meta-analysis of randomized trials comparing immune checkpoint inhibitors against chemotherapy as second line therapy in EGFR-mutant advanced NSCLC concluded immune checkpoint inhibitors do not improve OS over that with docetaxel [31]. A recent study presented in 2017 ASCO annual meeting also shows that NSCLCs harboring MET exon-14 alterations responded poorly to immunotherapy, even in PD-L1 positive patients (http://abstracts.asco.org/199/AbstView_199_189471.html). Moreover, a small percentage of patients develop hyper-progressive disease (HPD) after treatment with immune checkpoint inhibitors, and this hyper-progression appears to be associated with MDM2 amplification or EGFR alterations in a recent study [32]. We also need to consider AEs when TKIs and immunotherapy are administered concurrently or sequentially. For example, in EGFR-mutant NSCLCs, nivolumab and erlotinib combination was associated with 19% of grade 3 toxicities, and osimertinib and durvalumab combination resulted in significantly elevated incidence of interstitial lung disease [33]. In our case, the patient experienced colitis and pneumonitis upon pembrolizumab treatment, although they were mitigated through systemic steroids. Nevertheless, extra caution should be exercised to ensure sequential or concurrent treatment with targeted TKIs and immunotherapy are applied safely.

In conclusion, here we present a unique case of NSCLC where we transitioned an advanced lung cancer into a chronic disease in a geriatric patient. Sequential treatment with BRAF-TKIs and immunotherapy could provide significant clinical benefit to metastatic lung adenocarcinomas positive for both BRAF V600E and PD-L1.

Abbreviations

NSCLC: 

non-small cell lung cancer

TKI: 

tyrosine kinase inhibitor

CGP: 

comprehensive genomic profiling

AE: 

adverse event

OS: 

overall survival

PFS: 

progression-free survival

TMB: 

tumor mutation burden

Declarations

Authors’ contributions

JJL designed the study. AM, ABS, and JJL collected the data. SDL, AM, ABS and JJL analyzed and interpreted the data. SDL and JJL wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Dr. Paul Fishkin for helpful discussion of this work.

Competing interests

AM and JJL declare no competing interest. SDL is an employee of Sema4, a Mount Sinai venture. ABS in an employee of Foundation Medicine, Inc. with stock ownership.

Availability of data and materials

Not applicable.

Consent for publication

Informed consent was obtained from the patient.

Ethics approval and consent to participate

Need for approval was waived. Informed consent was obtained from the patient.

Funding

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai
(2)
Sema4
(3)
Department of Internal Medicine, OSF St., Francis Medical Center, University of Illinois College of Medicine at Peoria
(4)
Foundation Medicine, Inc.
(5)
Illinois CancerCare, P.C.

References

  1. Dholaria B, Hammond W, Shreders A, Lou Y. Emerging therapeutic agents for lung cancer. J Hematol Oncol. 2016;9(1):138.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomak Res. 2017;5:12.View ArticleGoogle Scholar
  3. Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9(1):47.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, Wolf J, Peters S, Fruh M, Koeberle D, et al. Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF cohort. J Thorac Oncol. 2015;10(10):1451–7.View ArticlePubMedGoogle Scholar
  5. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. New Engl J Med. 2015;373(8):726–36.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17(7):984–93.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(5):642–50.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Janne PA, Verma S, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34(7):721–30.View ArticlePubMedGoogle Scholar
  9. Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5(8):850–9.View ArticlePubMedGoogle Scholar
  10. Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842–9.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016;17(12):1653–60.View ArticlePubMedGoogle Scholar
  12. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630–5.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. New Engl J Med. 2006;354(24):2619–21.View ArticlePubMedGoogle Scholar
  14. Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997–2003.View ArticlePubMedGoogle Scholar
  15. Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol. 2012;30(25):3084–92.View ArticlePubMedGoogle Scholar
  16. Casadei Gardini A, Chiadini E, Faloppi L, Marisi G, Delmonte A, Scartozzi M, Loretelli C, Lucchesi A, Oboldi D, Dubini A, et al. Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC cancer. 2016;16:429.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med. 2015;372(26):2509–20.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med. 2006;355(24):2542–50.View ArticlePubMedGoogle Scholar
  20. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.View ArticlePubMedGoogle Scholar
  21. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med. 2002;346(2):92–8.View ArticlePubMedGoogle Scholar
  22. Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Janne PA, Johnson BE. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol. 2016;11(4):556–65.View ArticlePubMedGoogle Scholar
  23. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl J Med. 2010;362(25):2380–8.View ArticlePubMedGoogle Scholar
  24. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8.View ArticlePubMedGoogle Scholar
  25. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med. 2009;361(10):947–57.View ArticlePubMedGoogle Scholar
  26. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.View ArticlePubMedGoogle Scholar
  27. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.View ArticlePubMedGoogle Scholar
  28. Alexander GS, Palmer JD, Tuluc M, Lin J, Dicker AP, Bar-Ad V, Harshyne LA, Louie J, Shaw CM, Hooper DC, et al. Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. J Hematol Oncol. 2016;9(1):96.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–508.View ArticlePubMedGoogle Scholar
  30. Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2969–79.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, Yang JC. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis. J Thorac Oncol. 2017;12(2):403–7.View ArticlePubMedGoogle Scholar
  32. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242–50.View ArticlePubMedGoogle Scholar
  33. Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K. EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf. 2017;16(4):465–9.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement